Su Qihang, Cai Qiuchen, Feng Xiaofei, Huang Chenglong, Ge Heng'an, Chen Liyang, Xue Chao, Liu Centao, Li Jun, Cheng Biao
Department of Sports Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Orthop Surg. 2024 Aug;16(8):1980-1990. doi: 10.1111/os.14156. Epub 2024 Jul 3.
Weight is an influential factor in knee osteoarthritis (KOA). However, the effect of abnormal body weight on chitosan's efficacy in treating KOA is unclear. This study aimed to explore the differences in the effectiveness of arthroscopic surgery combined with intra-articular chitosan injection for KOA in patients with abnormal body weight.
Patients with stage II-III KOA (Kellgren-Lawrence rating, K-L) undergoing arthroscopic surgery were recruited for this clinical study from January 2020 to September 2021. Based on body mass index (BMI) and intra-articular chitosan injection, patients with KOA undergoing arthroscopic surgery (138 patients) were divided into four groups: low-weight-non-injection (Lw-N, BMI <18.5); low-weight-chitosan injection (Lw-CS, BMI <18.5); overweight-non-injection (Ow-N, BMI ≥25); overweight-chitosan injection (Ow-CS, BMI ≥25). A 2-year follow-up was conducted to evaluate various indicators, including the visual analogue scale (VAS) and the Western Ontario and McMaster Universities osteoarthritis index score (WOMAC). Statistical analyses were performed using relevant parametric or non-parametric tests.
In total, 138 patients with KOA were included in this study. There were no significant differences in gender, age, and incidence of chronic residual pain after arthroscopy among the four groups (p > 0.05). The proportion of patients undergoing subsequent knee arthroplasty during the 2-year follow-up period was significantly higher in the Ow-CS group (20/35) than in the Lw-CS group (12/39) (p < 0.05). The K-L rating showed an overall increasing trend over time, with the K-L rating in the Ow-N and Ow-CS groups significantly higher than that in the Lw-CS group at the final follow-up (p < 0.05). VAS and WOMAC scores significantly decreased at 1 and 3 months post-arthroscopy and then increased. One month after arthroscopy, VAS was significantly lower (p < 0.05) in the intra-articular chitosan injection groups (Lw-CS and Ow-CS) compared with the non-injection groups (Lw-N and Ow-N). VAS was lower in the Ow-CS group than in the Lw-CS group (p < 0.05). There was no significant difference in WOMAC between the intra-articular chitosan injection and non-injection groups at each time point (Lw-N vs. Lw-CS, Ow-N vs. Ow-CS, p > 0.05).
Arthroscopic surgery combined with intra-articular chitosan injection shows short-term positive effects in treating KOA. Intra-articular chitosan injection appears to have a greater short-term pain relief effect in obese patients.
体重是膝关节骨关节炎(KOA)的一个影响因素。然而,体重异常对壳聚糖治疗KOA疗效的影响尚不清楚。本研究旨在探讨关节镜手术联合关节腔内注射壳聚糖治疗体重异常的KOA患者的疗效差异。
2020年1月至2021年9月,招募接受关节镜手术的II-III期KOA(Kellgren-Lawrence分级,K-L)患者进行本临床研究。根据体重指数(BMI)和关节腔内注射壳聚糖,将接受关节镜手术的KOA患者(138例)分为四组:低体重-未注射组(Lw-N,BMI<18.5);低体重-壳聚糖注射组(Lw-CS,BMI<18.5);超重-未注射组(Ow-N,BMI≥25);超重-壳聚糖注射组(Ow-CS,BMI≥25)。进行为期2年的随访,以评估包括视觉模拟量表(VAS)和西安大略和麦克马斯特大学骨关节炎指数评分(WOMAC)等各项指标。使用相关的参数或非参数检验进行统计分析。
本研究共纳入138例KOA患者。四组患者在性别、年龄和关节镜检查后慢性残留疼痛发生率方面无显著差异(p>0.05)。在2年随访期内,Ow-CS组(20/35)接受后续膝关节置换术的患者比例显著高于Lw-CS组(12/39)(p<0.05)。K-L分级随时间总体呈上升趋势,最终随访时,Ow-N组和Ow-CS组的K-L分级显著高于Lw-CS组(p<0.05)。关节镜检查后1个月和3个月时,VAS和WOMAC评分显著降低,然后升高。关节镜检查后1个月,关节腔内注射壳聚糖组(Lw-CS和Ow-CS)的VAS显著低于未注射组(Lw-N和Ow-N)(p<0.05)。Ow-CS组的VAS低于Lw-CS组(p<0.